Holen Sie sich die Stockscreener-App
42.86
2.12%
0.89
Schlusskurs vom Vortag:
$41.97
Offen:
$41.61
24-Stunden-Volumen:
1.33M
Relative Volume:
0.83
Marktkapitalisierung:
$4.07B
Einnahmen:
$4.72M
Nettoeinkommen (Verlust:
$-277.91M
KGV:
-11.49
EPS:
-3.73
Netto-Cashflow:
$-203.56M
1W Leistung:
+0.45%
1M Leistung:
+0.02%
6M Leistung:
+43.11%
1J Leistung:
-24.85%
1-Tages-Spanne:
$41.51
$43.77
1-Wochen-Bereich:
$41.51
$45.16
52-Wochen-Spanne:
$24.10
$60.34
Crinetics Pharmaceuticals Inc Stock (CRNX) Company Profile
Firmenname
Crinetics Pharmaceuticals Inc
Sektor
Branche
Telefon
858-450-6464
Adresse
6055 LUSK BLVD., SAN DIEGO, CA
Vergleichen Sie CRNX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CRNX
Crinetics Pharmaceuticals Inc
|
42.86 | 3.98B | 4.72M | -277.91M | -203.56M | -3.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Crinetics Pharmaceuticals Inc Stock (CRNX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-10 | Eingeleitet | Goldman | Neutral |
| 2025-03-25 | Eingeleitet | Stifel | Buy |
| 2025-02-11 | Eingeleitet | TD Cowen | Buy |
| 2025-02-04 | Eingeleitet | Wolfe Research | Peer Perform |
| 2025-01-22 | Hochstufung | Jefferies | Hold → Buy |
| 2024-03-06 | Eingeleitet | Citigroup | Buy |
| 2024-01-16 | Eingeleitet | Morgan Stanley | Overweight |
| 2023-12-21 | Eingeleitet | Jefferies | Hold |
| 2023-11-20 | Fortgesetzt | JP Morgan | Overweight |
| 2023-10-24 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2023-08-31 | Eingeleitet | Oppenheimer | Outperform |
| 2023-04-24 | Eingeleitet | Piper Sandler | Overweight |
| 2023-03-30 | Eingeleitet | Robert W. Baird | Outperform |
| 2021-11-30 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2021-11-23 | Eingeleitet | Evercore ISI | Outperform |
| 2021-06-18 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-12-23 | Eingeleitet | ROTH Capital | Buy |
| 2019-02-14 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-08-13 | Eingeleitet | JP Morgan | Neutral |
| 2018-08-13 | Eingeleitet | Leerink Partners | Outperform |
| 2018-08-13 | Eingeleitet | Piper Jaffray | Overweight |
Alle ansehen
Crinetics Pharmaceuticals Inc Aktie (CRNX) Neueste Nachrichten
What technical signals suggest for Crinetics Pharmaceuticals Inc. stockTake Profit & Risk Controlled Stock Pick Alerts - newser.com
United States Congenital Adrenal Hyperplasia Treatment - openPR.com
Can Crinetics Pharmaceuticals Inc. stock sustain revenue growthJuly 2025 Movers & Daily Risk Controlled Trade Plans - newser.com
Is Crinetics Pharmaceuticals Inc. stock a safe haven assetPortfolio Risk Summary & Real-Time Sentiment Analysis - newser.com
How strong dollar benefits Crinetics Pharmaceuticals Inc. (6Z4) stockGlobal Markets & High Return Stock Watch Alerts - newser.com
Price-Driven Insight from (CRNX) for Rule-Based Strategy - news.stocktradersdaily.com
Crinetics begins Phase 3 trial of oral therapy for carcinoid syndrome - Investing.com Nigeria
Crinetics Pharmaceuticals Begins Phase 3 Trial of Paltusotine in Carcinoid Syndrome - MarketScreener
Crinetics (CRNX) Begins Phase 3 Trial for Paltusotine Treatment - GuruFocus
Crinetics announces first patient randomized in pivotal phase 3 CAREFNDR trial evaluating paltusotine in carcinoid syndrome - MarketScreener
Crinetics Announces First Patient Randomized in Pivotal Phase 3 CAREFNDR Trial Evaluating Paltusotine in Carcinoid Syndrome - The Manila Times
Crinetics Pharmaceuticals Advances Phase 3 CAREFNDR Trial for Paltusotine in Treating Carcinoid Syndrome - Quiver Quantitative
Crinetics (Nasdaq: CRNX) Starts Phase 3 CAREFNDR Trial for 141 Carcinoid Patients - Stock Titan
Using data tools to time your Crinetics Pharmaceuticals Inc. exit2025 Year in Review & Fast Gain Stock Trading Tips - newser.com
Sector ETF performance correlation with Crinetics Pharmaceuticals Inc.Entry Point & High Accuracy Swing Trade Signals - newser.com
Why Crinetics Pharmaceuticals Inc. (6Z4) stock attracts HNW investors2025 Major Catalysts & Real-Time Sentiment Analysis - newser.com
Is Crinetics Pharmaceuticals Inc. (6Z4) stock cheap by valuation metricsMarket Volume Summary & Safe Capital Growth Trade Ideas - newser.com
Is Crinetics Pharmaceuticals Inc. stock a safe buy before earningsQuarterly Trade Report & Risk Adjusted Buy/Sell Alerts - newser.com
Is Crinetics Pharmaceuticals Inc. stock entering bullish territoryJuly 2025 Closing Moves & Daily Momentum Trading Reports - newser.com
Crinetics Pharmaceuticals Inc.’s volatility index tracking explained2025 Buyback Activity & Reliable Entry Point Alerts - newser.com
Can Crinetics Pharmaceuticals Inc. rally from current levels2025 Year in Review & Short-Term Trading Opportunity Alerts - newser.com
What institutional flow reveals about Crinetics Pharmaceuticals Inc. - newser.com
Is Crinetics Pharmaceuticals Inc. (6Z4) stock supported by free cash flowMarket Growth Summary & Free High Return Stock Watch Alerts - newser.com
Quantitative breakdown of Crinetics Pharmaceuticals Inc. recent moveJuly 2025 Movers & Expert Approved Momentum Ideas - newser.com
Automated trading signals detected on Crinetics Pharmaceuticals Inc.Long Setup & AI Enhanced Market Trend Forecasts - newser.com
Will Crinetics Pharmaceuticals Inc. stock deliver better than expected guidance2025 Historical Comparison & Free Expert Approved Momentum Trade Ideas - newser.com
Chart based analysis of Crinetics Pharmaceuticals Inc. trendsMarket Sentiment Review & Long-Term Capital Growth Strategies - newser.com
Top chart patterns to watch in Crinetics Pharmaceuticals Inc.2025 Year in Review & Free Expert Verified Stock Movement Alerts - newser.com
Backtesting results for Crinetics Pharmaceuticals Inc. trading strategiesStop Loss & Long-Term Safe Investment Ideas - newser.com
Finanzdaten der Crinetics Pharmaceuticals Inc-Aktie (CRNX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.38%
1.42%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):